A new study finds that Medicare recipients can prevent hospital admissions if they seek medical assessment from clinical home visits, which increase the number of visits to the doctors while reducing the costs of healthcare because of treatment in less-costly sites.
A new study finds that Medicare recipients can prevent hospital admissions if they seek medical assessment from clinical home visits, which increase the number of visits to the doctors while reducing the costs of healthcare because of treatment in less-costly sites.
Soeren Mattke, senior scientist at Rand Corporation, led the new study along with Dan Han, Asa Wilks, and Elizabeth Sloss. The study used quantitative and qualitative data from patients enrolled in the HouseCalls program operated by UnitedHealth Group’s information and technology-enabled health services business, Optum. Under this program, a physician or nurse practitioner visits the Medicare recipient’s home and conducts an exhaustive geriatric assessment of their health. They also provide referrals to community providers and health plan resources to address any pending issues.
The team studied the experiences of the Medicare beneficiaries eligible for the HouseCalls program from 2008 through 2012. The scope of the study was spread across Arkansas, Georgia, Missouri, South Carolina, and Texas.
A majority of the Medicare recipients included in the study were 65 years old and were likely to have multiple chronic conditions in 2010. The beneficiaries also had troubles receiving primary care, either because of financial issues or social. This eventually would have increased the chances of their symptoms worsening resulting in emergency room visits, hospitalizations, and nursing home admissions.
The experiences of these beneficiaries were compared to other Medicare recipients enrolled both in traditional fee-for-service Medicare plans and in Medicare Advantage plans without this benefit.
The team observed that sending a physician or nurse practitioner to a Medicare recipient's home for a comprehensive health assessment resulted in fewer admissions to hospitals or nursing homes over the subsequent year. It also reduced the cost of getting admitted or being treated in hospitals that have their own costs associated.
When compared to other Medicare recipients enrolled in traditional fee-for-service health programs, the Medicare recipients enrolled in the clinical home visit program had 14% fewer hospital admissions in the next year. They even projected a lower risk of admission to nursing homes over the 12 months after evaluation.
The participants experienced an increase in their visits to the physicians and specialists. This increase to physicians was from 2% to 6% in the subsequent year after the evaluation. The program’s effects on the emergency department use was mixed and hence, inconclusive.
“We found that a home visiting program can lead to meaningful cuts in the amount of in-patient care used by Medicare patients,” said Mattke. “This is significant since many other strategies to reduce in-patient care among Medicare recipients generally have been unsuccessful.”
The findings of the study largely propose that a comprehensive health assessment provided at the beneficiary’s home encourages physician office visits and anticipates future illnesses that could result in costly institutional care. The positive combination of the home environment coupled with the referral services is a promising approach to supporting aging in place. It also avoids hospital admissions, which could increase the cost of healthcare for the Medicare beneficiary.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More